Observational Study of Infants Fed on DHA (Breast Source or Milk Formula Source ) and Its Effects on Covid-19 Infected Infants and Severity

Sponsor
Ministry of Health, Saudi Arabia (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05071690
Collaborator
Faculty of medicine kafr elshiekh university (Other)
100
2
2
50
24.9

Study Details

Study Description

Brief Summary

Observational Study of Infants Fed on DHA (Breast Source or Milk Formula Source ) and Its Effect on COVID-19 Severity

  • Amr kamel khalil Ahmed ( drmedahmed@gmail.com ) Director of tuberculosis program Ghubera, public health department ,First health cluster ,Ministry of health , Riyadh, Saudia Arabia https://orcid.org/0000-0003-3477-236X

  • Mahmoud Elkazzaz ( mahmoudramadan2051@yahoo.com ) Department of chemistry and biochemistry, Faculty of Science, Damietta University, Egypt https://orcid.org/0000-0003-3703-520X

Abstract

The novel SARS-CoV-2, which causes the disease called COVID-19, has rapidly spread across the globe. A striking and consistent observation has been the difference in severity of COVID-19 at different ages: severity, the need for hospitalization and mortality rise steeply with older age while severe disease and death are relatively rare in children and young adults. Most infants and children infected with SARS-CoV-2 are asymptomatic or have mild symptoms, most commonly fever, cough, pharyngitis, gastrointestinal symptoms and changes in sense of smell or taste. Whether infants and children are also less often infected by SARS-CoV-2 is an ongoing debate. Large epidemiological studies suggest that infants and children comprise only 1 to 2% of all SARS-CoV-2 cases. However, these numbers heavily depend on testing criteria and, in many reports, testing was done only in individuals who were symptomatic or required hospitalization, which is less often the case for children. Some studies suggest that infants and children are just as likely as adults to become infected with SARS-CoV-2.9 However, more recent studies report that children are less likely to get infected after contact with a SARS-CoV-2-positive individual.10-14 It has been suggested that children and adolescents have similar viral loads and may therefore be as likely to transmit SARS-CoV-2 as adults. In addition, the viral load may be similar in asymptomatic and symptomatic individuals. However, reassuringly, transmission in schools from children either to other children or to adults has been rare. The observation that children are less often infected with SARS-CoV-2 and that they have less severe symptoms is similar to that reported for SARS-CoV-1 and Middle East respiratory syndrome (MERS)-CoV. However, this pattern is strikingly different to that for infection with most other respiratory viruses (eg, respiratory syncytial virus (RSV), metapneumovirus, parainfluenza or influenza viruses), for which the prevalence and severity are both higher in children.Dr Amr kamel khalil Ahmed and Dr. Mahmoud Elkazzaz, the lead investigators of this observational study , recently published a preprint that demonstrated Docosahexaenoic acid (DHA) had a high binding affinity and greatest interactions with ACE2 active sites, as well as a moderate binding affinity and moderate interactions with the active sites of IL-6. The Docosahexaenoic acid (DHA) interacts with different active sites of IL6 and ACE2 which are involved in direct or indirect contacts with the ACE2 and IL-6 receptors which might act as potential blockers of functional ACE2 and IL-6 receptor complex. Docosahexaenoic acid (DHA) was detected in abundance in breast milk and other algal sources milk supplement used for newborns and children's feeding. As a result, we believe that docosahexaenoic acid (DHA) may protect children and newborns thorough competing with COVID-19 for ACE2 receptors and inhibiting IL-6 activity and may possibly help them avoid a cytokine storm and save their lives through inhibiting IL-6 and preventing SARS-CoV-2 RBD attachment to ACE2

Detailed Description

the study observational study case control study two groups of infants and children on DHA supplement A arm group on breast milk and measure the DHA level and determine the degree of severity of covid-19 symptoms according the classification of CDC the B arm infants on DHA at milk formula or DHA supplement and measure the DHA level and determine the severity of covid-19 according the classification of CDC

Study Design

Study Type:
Observational
Anticipated Enrollment :
100 participants
Observational Model:
Case-Control
Time Perspective:
Retrospective
Official Title:
COVID-19: Why Are Children Less Affected
Anticipated Study Start Date :
Nov 1, 2021
Anticipated Primary Completion Date :
Dec 1, 2021
Anticipated Study Completion Date :
Jan 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Arm 1

on breast milk 50 baby full-term and infant follow up for covid-19 symptoms and measurement of plasma DHA

arm 2

50 baby depend on DHA source like infant formula milk or supplement with DHA

Outcome Measures

Primary Outcome Measures

  1. the severity of COVID-19 symptoms at infants and children on DHA at milk formula and on breast feeding [6 month]

    comparison between two control groups infants and children on breast milk and group on milk formula nouriched at DHA

  2. measurement of percentage of plasma DHA at two groups of infants and children's [6 month]

    plasma DHA is very important to be measured

Secondary Outcome Measures

  1. THE duration of symptoms at two groups [6 month]

Eligibility Criteria

Criteria

Ages Eligible for Study:
1 Day to 5 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • full term baby infants and children until 5 years breast feeding or milk formula or supplement on DHA
Exclusion Criteria:
  • above 5 years no congenital diseases outside kingdom saudia arabia preterm

Contacts and Locations

Locations

Site City State Country Postal Code
1 Mahmoud Kafr Ash Shaykh Kafr Elshiekh Egypt 33511
2 Ministry of health.First health cluster ,Riaydh Riyadh Saudi Arabia

Sponsors and Collaborators

  • Ministry of Health, Saudi Arabia
  • Faculty of medicine kafr elshiekh university

Investigators

  • Principal Investigator: Amr K Ahmed, Ministry of Health, Saudia Arabia
  • Principal Investigator: Mahmoud R Elkazzaz, M.Sc of Biochemistry, Faculty of science Damietta university

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Amr kamel khalil Ahmed, Clinical Scientist, Ministry of Health, Saudi Arabia
ClinicalTrials.gov Identifier:
NCT05071690
Other Study ID Numbers:
  • Observational COVID-19 Study
First Posted:
Oct 8, 2021
Last Update Posted:
Oct 19, 2021
Last Verified:
Oct 1, 2021
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Amr kamel khalil Ahmed, Clinical Scientist, Ministry of Health, Saudi Arabia
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 19, 2021